Table 3.
Association between SII and primary outcomes in overall, diabetic and non-diabetic HFpEF patients
| Events (%) | Model 1 | Model 2 | Model 3 | ||||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Overall cohort | |||||||
| Log SII (Cont.) | 1.82 (1.46–2.26) | < 0.001 | 1.76 (1.41–2.19) | < 0.001 | 1.50 (1.18–1.92) | 0.001 | |
| SII1 | 52 (34.2) | Reference | Reference | Reference | |||
| SII2 | 67 (43.5) | 1.30 (0.91–1.87) | 0.156 | 1.27 (0.88–1.83) | 0.197 | 1.26 (0.85–1.88) | 0.249 |
| SII3 | 92 (60.5) | 2.22 (1.58–3.13) | < 0.001 | 2.12 (1.51–2.99) | < 0.001 | 1.70 (1.15–2.52) | 0.008 |
| With diabetes | |||||||
| Log SII (Cont.) | 2.07 (1.52–2.81) | < 0.001 | 2.06(1.49–2.85) | < 0.001 | 1.88 (1.32–2.67) | < 0.001 | |
| SII1 | 15 (31.9) | Reference | Reference | ||||
| SII2 | 30 (48.4) | 1.83 (0.98–3.40) | 0.056 | 1.60 (0.85–3.02) | 0.143 | 1.62 (0.83–3.14) | 0.157 |
| SII3 | 63 (75.0) | 3.40 (1.93–5.98) | < 0.001 | 3.25 (1.84–5.74) | < 0.001 | 2.63 (1.43–4.85) | 0.002 |
| Without diabete | |||||||
| Log SII (Cont.) | 1.47 (1.07–2.02) | 0.019 | 1.39 (1.01–1.92) | 0.042 | 1.23 (0.86–1.77) | 0.251 | |
| SII1 | 37 (35.2) | Reference | Reference | ||||
| SII2 | 37 (40.2) | 1.08 (0.68–1.70) | 0.750 | 1.08 (0.69–1.71) | 0.726 | 1.12 (0.66–1.89) | 0.675 |
| SII3 | 29 (42.6) | 1.42 (0.87–2.31) | 0.160 | 1.32 (0.80–2.15) | 0.276 | 1.13 (0.63–2.02) | 0.690 |
Model 1: Unadjusted model
Model 2: Adjusted for age and sex
Model 3: Adjusted for Model 2 + diabetes, CKD, heart rate, diastolic blood pressure, NTproBNP, creatinine, total cholesterol, HDL, HbA1c, E/e, LVEDD, and LVEF
CKD: chronic kidney disease, NTproBNP: N-terminal pro-B-type natriuretic peptide, HDL: high-density cholesterol, Hb1AC: glycated hemoglobin, LVEF: left ventricular ejection fraction, E/e: mean septal diastolic velocity, LVEDD: left ventricular end-diastolic dimension, SII: systemic immune-inflammation index, HR: hazard ratio, CI: confidence interval